Nair P, Wenzel SE, Rabe KF, et al. Benralizumab Significantly Reduced Oral Corticosteroid Dosages and Asthma Exacerbation Rates for Patients with Severe, Uncontrolled Asthma: Results of the ZONDA Phase III Trial. ATS 2017, abstract 5964,Nair P, Wenzel S, Rabe KF, et al. Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma. N Engl J Med. 2017 May 22. doi: 10.1056/NEJMoa1703501. [Epub ahead of print]
Radboud start fase I/II-studie naar COVID-19-vaccin
mrt 2021 | Vaccinatie, Virale infecties